Makino, T.; Sakurai, T.; Takamatsu, S.; Nakagawa, R.; Kamijima, T.; Kano, H.; Naito, R.; Iwamoto, H.; Yaegashi, H.; Shigehara, K.;
et al. Seven-Year PSA ≤ 0.2 ng/mL After High-Dose-Rate Brachytherapy Indicates Eligibility for Discontinuing PSA Surveillance in Prostate Cancer. Cancers 2025, 17, 3151.
https://doi.org/10.3390/cancers17193151
AMA Style
Makino T, Sakurai T, Takamatsu S, Nakagawa R, Kamijima T, Kano H, Naito R, Iwamoto H, Yaegashi H, Shigehara K,
et al. Seven-Year PSA ≤ 0.2 ng/mL After High-Dose-Rate Brachytherapy Indicates Eligibility for Discontinuing PSA Surveillance in Prostate Cancer. Cancers. 2025; 17(19):3151.
https://doi.org/10.3390/cancers17193151
Chicago/Turabian Style
Makino, Tomoyuki, Takayuki Sakurai, Shigeyuki Takamatsu, Ryunosuke Nakagawa, Taiki Kamijima, Hiroshi Kano, Renato Naito, Hiroaki Iwamoto, Hiroshi Yaegashi, Kazuyoshi Shigehara,
and et al. 2025. "Seven-Year PSA ≤ 0.2 ng/mL After High-Dose-Rate Brachytherapy Indicates Eligibility for Discontinuing PSA Surveillance in Prostate Cancer" Cancers 17, no. 19: 3151.
https://doi.org/10.3390/cancers17193151
APA Style
Makino, T., Sakurai, T., Takamatsu, S., Nakagawa, R., Kamijima, T., Kano, H., Naito, R., Iwamoto, H., Yaegashi, H., Shigehara, K., Nohara, T., Izumi, K., & Mizokami, A.
(2025). Seven-Year PSA ≤ 0.2 ng/mL After High-Dose-Rate Brachytherapy Indicates Eligibility for Discontinuing PSA Surveillance in Prostate Cancer. Cancers, 17(19), 3151.
https://doi.org/10.3390/cancers17193151
